文献库搜索 | GeneLibs

Vo(JN),Wu(YM),Wang(R),Pham(T),Cao(X),Yeung... medRxiv 2026-05-05

...PIK3CA, PDGFRB, and KIT with functionally synergistic activity. Haplotype phasing resolves a systematically overlooked g...

Xia(TY),Liu(XK),Jiang(HL),Xu(YB),Wang(JW),... Fitoterapia 2026-07-00

...PIK3CA and AKT1. The highly consistent chemical profiles and predicted therapeutic pathways solidly support the feasibil...

Yeni Yildirim(S),Selenica(P),Gazzo(A),Djer... Histopathology 2026-06-03

...PIK3CA and PTEN, were only present in MED12-wild type MPTs, and absent in MED12-mutant cases (15% vs. 0%; P > 0.05). Fur...

Huang(M),Yang(J),Peng(P),Wang(Y),Song(L),L... Int J Cancer 2026-09-15

...PIK3CA) mutations, 246 (2.78%) had Erb-B2 receptor tyrosine kinase 2 (ERBB2) mutations, 102 (1.15%) had B-Raf proto-onco...

Ekpo(P),Khattak(M),Cheung(T),Su(YY),Bains(... Res Sq 2026-05-18

...PIK3CA, vMYB and loss of CDKN2A. Tumor sequencing found a H1047R mutation in PIK3CA. STR profiling showed the propagated...

Yang(J),Li(J),Liu(M),Mao(Y),Su(R),Zhao(C),... Life (Basel) 2026-02-04

...PIK3CA, SRC). Enrichment analysis implicated these targets in focal adhesion, ECM-receptor interaction, and PI3K-Akt sig...

Hsia(B),Bitar(G),Bonilla(PS),Veluvolu(VD),... Life (Basel) 2026-02-06

...PIK3CA (26.0%), and KMT2D (21.6%). Gender-specific analyses suggested potential enrichment of TP53 and MET mutations in ...

Rossi(S),Pagliaro(A),Masini(S),Finocchiaro... Biomedicines 2026-02-04

...PIK3CA mutation subtypes or treatment strategies. Conclusions: PIK3CA-altered NSCLC represents a molecularly heterogeneo...

Saravanan(S),Arockiasamy(E) Cell Biochem Biophys 2026-06-00

...PIK3CA, and CYP19A1 are the main hub regulators and α-amylase, α –glucosidase which was the key enzymes involved in insu...

Fayed(S),Amer(S),Badawy(M),Bou Malhab(L),O... Int J Mol Sci 2026-02-20

...PIK3CA, are discussed within the context of GBM's mutational and signaling landscape. We further outline emerging CRISPR...